Sugi Predict

Sugi Predict / Compounds / SCHEMBL156294

SCHEMBL156294

SCHEMBL156294

Cc1ncn(-c2ccc(C#N)cc2F)n1

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ GPR119 Q8TDV5 2/20 0.38
▸ EGLN2 Q96KS0 6/20 0.37
▸ CRHR1 P34998 1/20 0.36
▸ AR P10275 1/20 0.36
▸ PRKDC P78527 1/20 0.36
▸ BAZ2B Q9UIF8 1/20 0.36
▸ BAZ2A Q9UIF9 1/20 0.36
▸ TRPA1 O75762 1/20 0.36
▸ CYP11B2 P19099 2/20 0.35
▸ ALOX5AP P20292 1/20 0.35
▸ MAP2K1 Q02750 1/20 0.35
▸ PSEN1 P49768 1/20 0.35
▸ PSEN2 P49810 1/20 0.35
▸ APH1B Q8WW43 1/20 0.35
▸ NCSTN Q92542 1/20 0.35
▸ APH1A Q96BI3 1/20 0.35
▸ PSENEN Q9NZ42 1/20 0.35
▸ CYP17A1 P05093 1/20 0.34
▸ CYP19A1 P11511 1/20 0.34
▸ CYP11B1 P15538 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL155501 0.80 AR (0.43) EGLN2ARPRKDCCYP11B2PSEN1
SCHEMBL16202018 0.80 PSEN1 (0.41) PSEN1PSEN2APH1BNCSTNAPH1A
SCHEMBL15465399 0.78 NR3C2 (0.41) GPR119EGLN2MAP2K1
SCHEMBL512436 0.77 MAPT (0.39) ALOX5APPSEN1PSEN2APH1BNCSTN
SCHEMBL15465711 0.77 NOTUM (0.47) GPR119EGLN2CYP11B2MAP2K1CYP11B1
SCHEMBL20094519 0.75 PSEN1 (0.35) MAP2K1PSEN1PSEN2APH1BNCSTN
SCHEMBL20085553 0.75 PSEN1 (0.35) CRHR1TRPA1PSEN1PSEN2APH1B
SCHEMBL1955774 0.74 EP300 (0.43) EGLN2ARCYP11B2CYP19A1CYP11B1
SCHEMBL2076006 0.73 KDM4E (0.36) EGLN2ARCYP11B2ALOX5APPSEN1
SCHEMBL1457885 0.73 USP30 (0.46) EGLN2PSEN1PSEN2APH1BNCSTN

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8901309-B2 Fused triazoles for the treatment or prophylaxis of mild cognitive impairment TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2014-12-02 — — US disclosed
US-20140350260-A1 HETEROCYCLIC COMPOUND AND USE THEREOF TAKEDA PHARMACEUTICAL (JP) 2014-11-27 — — US disclosed
US-8822699-B2 Heterocyclic compound and use thereof TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2014-09-02 — — US disclosed
US-20130178497-A1 FUSED TRIAZOLES FOR THE TREATMENT OR PROPHYLAXIS OF MILD COGNITIVE IMPAIRMENT TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2013-07-11 — — US disclosed
US-20120059030-A1 HETEROCYCLIC COMPOUND AND USE THEREOF TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2012-03-08 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130178497-A1 FUSED TRIAZOLES FOR THE TREATMENT OR PROPHYLAXIS OF MILD COGNITIVE IMPAIRMENT BACE1, BACE2, APP GPR119 420/4885EGLN2 4761/4885CRHR1 2420/4885
US-20120059030-A1 HETEROCYCLIC COMPOUND AND USE THEREOF BACE1, BACE2, APP GPR119 624/4885EGLN2 4190/4885CRHR1 3030/4885
US-20140350260-A1 HETEROCYCLIC COMPOUND AND USE THEREOF BACE1, BACE2, APP GPR119 624/4885EGLN2 4190/4885CRHR1 3030/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.